Ranbaxy recalls some batches of generic Lipitor in latest quality blow

MUMBAI Sat Mar 8, 2014 4:19pm IST

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013. REUTERS/Adnan Abidi/Files

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013.

Credit: Reuters/Adnan Abidi/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.NS), reeling under a flurry of regulatory rebukes due to manufacturing quality concerns, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after doseage mix-up was detected.

Ranbaxy recalled tablets of atorvastatin calcium, the generic version of Pfizer Inc's (PFE.N) cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the U.S. Food and Drug Administration (FDA) said on its website.

Ranbaxy, India's biggest drugmaker by revenue and majority owned by Japan's Daiichi Sankyo Co Ltd (4568.T), confirmed the recall of select batches of the drug, but said the company had not received any product complaints.

"Ranbaxy is proactively recalling the lots out of an abundance of caution, keeping the safety of its patients in mind and with the full knowledge of the U.S. FDA," the company said in a statement issued to Reuters on Saturday.

The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States, its biggest market.

Ranbaxy-owned Ohm Laboratories Inc in New Jersey is now the company's only permitted maker of drugs for U.S. sale.

Worries about quality control in India's $14 billion drug industry have come to the fore in the past year as plants run by Ranbaxy and local rival Wockhardt Ltd (WCKH.NS) have been banned after falling short of the FDA's "good manufacturing practices".

India's drugmakers have come under closer scrutiny as the FDA, the guardian of the world's most important pharmaceuticals market, has increased its presence in the country, reflecting India's growing importance as a supplier to the United States.

Indian generic drugmakers such as Ranbaxy, Wockhardt and Dr Reddy's Laboratories Ltd (REDY.NS) produce nearly 40 percent of generic drugs and over-the-counter products and 10 percent of finished dosages used in the United States.

CLASS II RECALL

The FDA declared the recall of Lipitor generic by Ranbaxy as Class II, which signifies a remote chance of severe adverse consequences or death due to the product flaw. This, however, is not the first time the company has recalled the drug.

In November 2012, Ranbaxy had recalled certain lots of the widely used cholesterol lowering medicine after it discovered contamination with tiny glass particles.

Ranbaxy had stopped manufacturing the blockbuster drug as it sought to fix the issues that resulted in the recall. It resumed production for sale in the United States in February last year.

Last month, the FDA prohibited Ranbaxy from shipping to the United States any pharmaceutical ingredient made at its Toansa plant in northern Indian following an inspection that found poor manufacturing practices.

The ban, which followed similar actions at two plants in 2008 including Dewas and another in September 2013, has triggered scrutiny by FDA counterparts in other countries including in India.

Ranbaxy shares have lost 18 percent so far this year, compared with a 4 percent gain for the NSE Index .NSEI.

(Additional reporting by Mridhula Raghavan and Aditya Kondalamahanty in BANGALORE; Writing by Sumeet Chatterjee; Editing by Ken Wills & Kim Coghill)

FILED UNDER:

Market Eye

REUTERS SHOWCASE

Setback For Sahara

Setback For Sahara

Supreme Court defers verdict on Sahara plea to raise more debt on hotels  Full Article 

SpiceJet Crisis

SpiceJet Crisis

SpiceJet says fleet grounded on lack of fuel  Full Article 

Drug Patents

Drug Patents

Novartis sues Cipla over respiratory drug Onbrez   Full Article 

Boost for Tata Steel

Boost for Tata Steel

Tata Steel restarts key iron mines amid shortage  Full Article 

Reuters Poll

Reuters Poll

BSE Sensex to hit 32,980 by December 2015  Full Article 

India Outlook

India Outlook

ADB trims growth forecasts for developing Asia, says India to grow 5.5 pct in 2014  Full Article 

Real Estate

Real Estate

HDFC to raise $500 mln real estate private equity fund - sources  Full Article 

Banking Sector

Banking Sector

Japan banks to bulk up India presence on improving ties   Full Article 

U.S. Spending Bill

U.S. Spending Bill

Obama signs bill $1.1 trillion government spending bill  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage